HKMPY OTC
Hikma Pharmaceuticals PLC
1W: +0.5%
1M: +5.7%
3M: +0.5%
YTD: +6.3%
1Y: -5.2%
3Y: -9.6%
5Y: -22.4%
$44.35
+0.00 (+0.00%)
Credit Risk of going bust: lower than 53% of companies Debt: 29.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.43 (down 97%), Hikma Pharmaceuticals PLC would be worth roughly what it owes.
Total debt $1.96B against a stock market value of $4.64B.
Distance to default 5.38 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.04B (short-term plus half of long-term), stock volatility 38.0%; Altman Z'' 4.49. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $1.96B against a stock market value of $4.64B.
Distance to default 5.38 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.04B (short-term plus half of long-term), stock volatility 38.0%; Altman Z'' 4.49. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
📊 Key Metrics
TTM$3B
Revenue
+6.1% YoY
$386M
Net Income
+4.5% YoY
$149M
Free Cash Flow
-53.1% YoY
42.1%
Gross Margin
20.8%
Op. Margin
12.9%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE15.3%
ROA6.8%
ROIC12.1%
Valuation
P/E12.7
P/B1.9
EV/EBITDA6.9
Leverage
Debt/Equity0.78
Current Ratio1.98
Interest Cov.5.6x
Quality Scores
Piotroski F7/9
Altman Z2.66
Beneish M-2.44